5-azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in vitro and in vivo possibly by altering DNA methylation

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Jiang, Wei ^a   Li, Ying Qin ^a   Liu, Na ^a   Sun, Ying ^a   He, Qing Mei ^a   Jiang, Ning ^a   Xu, Ya Fei ^a   Chen, Lei ^a   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CELL DNA; ANTINEOPLASTIC ANTIMETABOLITE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CLONE; CELL CYCLE PROGRESSION; CELL STRAIN; CELL STRAIN CNE2; CELL STRAIN SUNE1; CELL SURVIVAL; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROMOTER REGION; PYROSEQUENCING; RADIATION RESPONSE; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETIC EPIGENESIS; GENETICS; RADIATION DOSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA REPAIR; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; MICE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898669639     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093273     Document Type: Article

References (44)

1. Wei WI, Sham JS (2005) Nasopharyngea (Pubitemid 40812341)
2. Lee AW, Fee WE, Jr., Ng WT, Chan LK (2012) Nasopharyngeal carcinoma: salvage of local recurrence. Oral Oncol 48: 768-774.
3. Lo KW, To KF, Huang DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423-428. (Pubitemid 38612865)
4. Qiu H, Yashiro M, Shinto O, Matsuzaki T, Hirakawa K (2009) DNA methyltransferase inhibitor 5-aza-CdR enhances the radiosensitivity of gastric cancer cells. Cancer Sci 100: 181-188.
5. Patties I, Jahns J, Hildebrandt G, Kortmann RD, Glasow A (2009) Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines. Strahlenther Onkol 185: 331-338.
6. Hofstetter B, Niemierko A, Forrer C, Benhattar J, Albertini V, et al. (2010) Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys 76: 1512-1519.
7. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428. (Pubitemid 34587077)
8. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
9. Kim HJ, Kim JH, Chie EK, Young PD, Kim IA, et al. (2012) DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 7: 39.
10. Lo KW, To KF, Huang DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423-428. (Pubitemid 38612865)
11. Kwong J, Lo KW, To KF, Teo PM, Johnson PJ, et al. (2002) Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin Cancer Res 8: 131-137. (Pubitemid 34101468)
12. Wong TS, Kwong DL, Sham JS, Wei WI, Yuen AP (2005) Methylation status of Reprimo in head and neck carcinomas. Int J Cancer 117: 697. (Pubitemid 41504562)
13. Yang H, Zhao R, Lee MH (2006) 14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma. Mol Cancer Ther 5: 253-260.
14. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319. (Pubitemid 30437320)
15. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, et al. (1999) Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 81: 1122-1126.
16. Xu M, Knox AJ, Michaelis KA, Kiseljak-Vassiliades K, Kleinschmidt- DeMasters BK, et al. (2012) Reprimo (RPRM) is a novel tumor suppressor in pituitary tumors and regulates survival, proliferation, and tumorigenicity. Endocrinology 153: 2963-2973.
17. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, et al. (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505. (Pubitemid 27449237)
18. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463. (Pubitemid 38715140)
19. Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62: 679-694. (Pubitemid 19194494)
20. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
21. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ (1986) Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115. (Pubitemid 16075915)
22. Andorfer P, Rotheneder H (2011) EAPP: gatekeeper at the crossroad of apoptosis and p21-mediated cell-cycle arrest. Oncogene 30: 2679-2690.
23. Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, et al. (2011) gamma-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol Biol 682: 249-270.
24. Malpeli G, Amato E, Dandrea M, Fumagalli C, Debattisti V, et al. (2011) Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. BMC Cancer 11: 351.
25. Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, et al. (2009) Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res 15: 5696-5703.
26. Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue CA, Yeo CJ, et al. (2006) Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer 107: 251-257. (Pubitemid 44036553)
27. Carr M, Chavez-Munoz C, Lai A, Ghahary A (2011) Dermal fibroblasts influence the expression profile of 14-3-3 proteins in human keratinocytes. Mol Cell Biochem 353: 205-214.
28. Xing J, Wu X, Vaporciyan AA, Spitz MR, Gu J (2008) Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 112: 2756-2764. (Pubitemid 351969221)
29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
30. Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2: 2265-2275. (Pubitemid 351575045)
31. Barendsen GW (1997) Parameters of linear-quadratic radiation dose-effect relationships: dependence on LET and mechanisms of reproductive cell death. Int J Radiat Biol 71: 649-655. (Pubitemid 27306020)
32. Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, et al. (2007) The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5- azacytidine in human bladder cancer therapy. Int J Cancer 120: 1795-1802. (Pubitemid 46399368)
33. Muschel RJ, Soto DE, McKenna WG, Bernhard EJ (1998) Radiosensitization and apoptosis. Oncogene 17: 3359-3363. (Pubitemid 29043988)
34. Brieger J, Mann SA, Pongsapich W, Koutsimpelas D, Fruth K, et al. (2012) Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med 29: 505-509.
35. Yang Q, Shan L, Yoshimura G, Nakamura M, Nakamura Y, et al. (2002) 5-aza-2'-deoxycytidine induces retinoic acid receptor beta 2 demethylation, cell cycle arrest and growth inhibition in breast carcinoma cells. Anticancer Res 22: 2753-2756. (Pubitemid 36069308)
36. Wang XM, Wang X, Li J, Evers BM (1998) Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann Surg 227: 922-931. (Pubitemid 29119540)
37. Shrivastav M, De Haro LP, Nickoloff JA (2008) Regulation of DNA doublestrand break repair pathway choice. Cell Res 18: 134-147.
38. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA doublestranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868. (Pubitemid 28124064)
39. De Schutter H, Kimpe M, Isebaert S, Nuyts S (2009) A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 73: 904-912.
40. Zheng Z, Li L, Liu X, Wang D, Tu B, et al. (2012) 5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J 26: 449-459.
41. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799. (Pubitemid 39070849)
42. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10: 699-703. (Pubitemid 32331578)
43. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, et al. (1998) Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4: 685-690. (Pubitemid 28274668)
44. Al-Khalaf HH, Colak D, Al-Saif M, Al-Bakheet A, Hendrayani SF, et al. (2011) p16( INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS One 6: e21111.